Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Helsinn's anamorelin approval chances plummet on mixed PhIII cachexia data

This article was originally published in Scrip

Executive Summary

Switzerland's Helsinn Group has presented results from two Phase III studies of cachexia drug anamorelin, with which it is planning 2015 filings in the US and Europe. But while the drug hit one of its co-primary endpoints, its failure to hit the second makes its success questionable.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026493

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel